Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States; Department of Physiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning, China.
Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.
Cell Immunol. 2019 Jan;335:22-29. doi: 10.1016/j.cellimm.2018.10.008. Epub 2018 Oct 26.
Although hematopoietic stem cell transplantation (HSCT) has been widely used in the treatment of many diseases, graft-versus-host disease (GVHD) remains a major complication after allogeneic HSCT. Butyrophilin-like 2 (BTNL2) protein has been reported to have the ability to inhibit T cell proliferation in vitro; its ability to inhibit T cell responses in vivo has not been determined. We show here that in vivo administration of recombinant BTNL2-IgG2a Fc (rBTNL2-Ig) fusion protein ameliorates GVHD in mice. This is related to the ability of rBTNL2-Ig to inhibit T cell proliferation, activation and Th1/Th17 cytokine production in vivo. Furthermore, rBTNL2-Ig treatment increases the generation of regulatory T cells. Our results suggest that rBTNL2-Ig has the potential to be used in the prevention and treatment of patients with GVHD.
虽然造血干细胞移植（HSCT）已被广泛应用于治疗多种疾病，但移植物抗宿主病（GVHD）仍然是异基因 HSCT 后的主要并发症。有报道称，BTNL2 样蛋白 2（BTNL2）具有体外抑制 T 细胞增殖的能力，但它在体内抑制 T 细胞反应的能力尚未确定。我们在这里表明，体内给予重组 BTNL2-IgG2a Fc（rBTNL2-Ig）融合蛋白可改善小鼠的 GVHD。这与 rBTNL2-Ig 抑制 T 细胞增殖、体内 T 细胞活化和 Th1/Th17 细胞因子产生的能力有关。此外，rBTNL2-Ig 治疗可增加调节性 T 细胞的产生。我们的研究结果表明，rBTNL2-Ig 有可能用于预防和治疗 GVHD 患者。
